EPISODE · Apr 20, 2026 · 5 MIN
Medicus Pharma files Orphan Drug application for SkinJect in rare skin Cancer indication
from Proactive - Interviews for investors · host Proactive Investors
Medicus Pharma CEO Dr Raza Bokhari joined Steve Darling from Proactive to announce that the company has submitted an Orphan Drug Designation application to the U.S. Food and Drug Administration for SkinJect® as a treatment for basal cell carcinoma in patients with Gorlin Syndrome. Bokhari explained that the submission represents a strategic expansion of the SkinJect program into a high unmet-need orphan indication, where current treatment options are limited and often require repeated surgical procedures that can lead to cumulative morbidity and disfigurement. Gorlin Syndrome, also known as nevoid basal cell carcinoma syndrome, is a rare inherited disorder typically caused by mutations in the PTCH1 gene. This leads to dysregulation of the Hedgehog signaling pathway and the development of multiple, recurring skin cancers. Patients may develop dozens to more than 1,000 basal cell carcinomas over their lifetime, often beginning in childhood, creating a significant physical and psychological burden. Currently, there are no FDA-approved therapies specifically for basal cell carcinoma in patients with Gorlin Syndrome, with treatment largely reliant on surgical excision or Mohs surgery. Medicus believes SkinJect® could address this gap through a localized, repeatable, and non-surgical approach. The therapy is a doxorubicin-based dissolvable microneedle array designed for direct intradermal delivery into basal cell carcinoma lesions, targeting tumors at the site while minimizing systemic exposure. The company sees this program as an opportunity to provide a more patient-friendly treatment option for a population with significant unmet medical need. Medicus also noted it has sufficient financial runway into next year to support continued advancement of its clinical programs and key development milestones. #proactiveinvestors #nasdaq #mdcx #tsxv #mdcx #pharma #SkinJect #OrphanDrug #RareDisease #GorlinSyndrome #BasalCellCarcinoma #SkinCancer #Biotech #DrugDevelopment #FDA #Oncology #MedicalInnovation #Healthcare #Microneedle #PatientCare
What this episode covers
Medicus Pharma CEO Dr Raza Bokhari joined Steve Darling from Proactive to announce that the company has submitted an Orphan Drug Designation application to the U.S. Food and Drug Administration for SkinJect® as a treatment for basal cell carcinoma in patients with Gorlin Syndrome. Bokhari explained that the submission represents a strategic expansion of the SkinJect program into a high unmet-need orphan indication, where current treatment options are limited and often require repeated surgical procedures that can lead to cumulative morbidity and disfigurement. Gorlin Syndrome, also known as nevoid basal cell carcinoma syndrome, is a rare inherited disorder typically caused by mutations in the PTCH1 gene. This leads to dysregulation of the Hedgehog signaling pathway and the development of multiple, recurring skin cancers. Patients may develop dozens to more than 1,000 basal cell carcinomas over their lifetime, often beginning in childhood, creating a significant physical and psychological burden. Currently, there are no FDA-approved therapies specifically for basal cell carcinoma in patients with Gorlin Syndrome, with treatment largely reliant on surgical excision or Mohs surgery. Medicus believes SkinJect® could address this gap through a localized, repeatable, and non-surgical approach. The therapy is a doxorubicin-based dissolvable microneedle array designed for direct intradermal delivery into basal cell carcinoma lesions, targeting tumors at the site while minimizing systemic exposure. The company sees this program as an opportunity to provide a more patient-friendly treatment option for a population with significant unmet medical need. Medicus also noted it has sufficient financial runway into next year to support continued advancement of its clinical programs and key development milestones. #proactiveinvestors #nasdaq #mdcx #tsxv #mdcx #pharma #SkinJect #OrphanDrug #RareDisease #GorlinSyndrome #BasalCellCarcinoma #SkinCancer #Biotech #DrugDevelopment #FDA #Oncology #MedicalInnovation #Healthcare #Microneedle #PatientCare
NOW PLAYING
Medicus Pharma files Orphan Drug application for SkinJect in rare skin Cancer indication
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.